Rappta Therapeutics and SpringWorks Forge a License Agreement for RPT04402 Targeting Uterine Cancer Treatments Rappta Therapeutics has formed an exclusive global licensing agreement with SpringWorks for the development of RPT04402, targeting PP2A for uterine cancers.

Rappta Therapeutics and SpringWorks Forge a License Agreement for RPT04402 Targeting Uterine Cancer Treatments #Finland #Helsinki #Rappta_Therapeutics #RPT04402 #SpringWorks_Therapeutics